Shaping a new era of global health investment, policy, planning and prevention
AVAC is part of a robust civil society movement helping to shape a new era of global health spending and planning related to HIV prevention. We mobilize to ensure programs, products and policies are evidence-based, inclusive and effective. With our partner network, we identify critical needs and develop strategic campaigns to advance HIV prevention, with a focus on ensuring a rich pipeline of options move through research and development, and rollout effectively to reach the communities who need them most.
Our advocacy takes place:
Blog Post
AVAC condemns a series of actions taken by the U.S. presidential administration to dismantle U.S. leadership in research, development and delivery of lifesaving vaccines. Without U.S. government leadership, the country and the world will remain woefully unprepared for ongoing and emerging pandemic threats.
presentation
This presentation, delivered by AVAC’s Executive Director, Mitchell Warren at IAS 2025, shares a sobering picture of the sweeping changes to science, global health and particularly, HIV R&D since January 20, 2025. It outlines the impact of foreign aid cuts, NIH grant terminations, and policy shifts and shares a vision for the future.
Blog Post
AVAC denounces recent proposals and actions by the US administration that signal a clear intention to defund and eliminate lifesaving global health research, development and delivery programs. If passed by Congress, proposed funding rescissions for the current year’s budget would claw back billions of Congressionally appropriated dollars for critical, life-saving programs.
Percentage of key population-serving implementing partners that have reported full or partial termination of the provision of KP services due to US funding cuts (as of April 2025).
Accelerating the development and delivery of STI prevention.
Using data for smarter advocacy and high-impact campaigns.
Developing an Africa-centered network dedicated to accelerating HIV prevention research, and advancing equitable access to proven HIV prevention products.
Late today in AVAC v Department of State and Global Health Council v Trump, the Supreme Court of the United States granted the US Presidential Administration’s request to stay an injunction that would require the Administration to obligate $4 billion of foreign assistance funds before they expire on September 30, as required by law. The Court’s ruling temporarily grants the Administration’s request to pause a lower court order that the government spend the funds. With just four days until September 30, those funds, which otherwise would have saved lives and advanced global health and national security, will remain unspent.
Hard-won gains in access to essential medicines, vaccines, and diagnostics are under siege from political retreat, corporate profiteering, and deadly funding cuts. Yet governments building local production and increasing domestic health investment, multilateral initiatives expanding pooled procurement and financing, and civil society breaking drug monopolies prove that progress is possible when lives are valued over profits. This event will chart how the world can keep advancing access to medicines—because retreat is not an option.
The US presidential administration’s funding cuts and policy shifts are reshaping the public health landscape in profound ways. While many of these changes have drawn significant media attention, the impact on sexually transmitted infection research and prevention has remained largely overlooked, though the consequences are dire, writes AVAC’s Alison Footman writes in TheBodyPro.